Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

NCT06961617 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: LioCyx-M, HBV antigen-specific TCR-redirected T cells

Sponsor

Lion TCR Pte. Ltd.

Collaborators

[object Object]